SPI-1005 Treatment in Moderate COVID-19 Patients
SPI-1005 Treatment in Moderate COVID-19 Patients
Enrolling by invitation · NCT04484025 · Registry updated 2023-10-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SPI-1005 Treatment in Moderate COVID-19 Patients | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Enrolling by invitation | Phase 2 | 2023-10-03 | NCT04484025 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sound Pharmaceuticals, Incorporated | 3 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University | Durham | United States | 160 |
| Kansas University Medical Center | Kansas City | United States | 25 |
| St. Luke's Cystic Fibrosis Center of Idaho | Boise | United States | 2 |
| University of Texas Southwestern | Dallas | United States | 73 |
| Wake Forest University | Winston-Salem | United States | 14 |
| Washington University in St. Louis | St Louis | United States | 35 |
| Yale University | New Haven | United States | 76 |